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Virus infection induces an antiviral response that is predominantly associated with the synthesis and
secretion of soluble interferon. Here, we report that herpes simplex virus type 1 virions induce an interferon-
independent antiviral state in human embryonic lung cells that prevents plaquing of a variety of viruses.
Microarray analysis of 19,000 human expressed sequence tags revealed induction of a limited set of host genes,
the majority of which are also induced by interferon. Genes implicated in controlling the intracellular spread
of virus and eliminating virally infected cells were among those induced. Induction of the cellular response
occurred in the absence of de novo cellular protein synthesis and required viral penetration. In addition, this
response was only seen when viral gene expression was inhibited, suggesting that a newly synthesized viral
protein(s) may function as an inhibitor of this response.
Mammalian cells respond to virus infection by launching a
transcription program that generates an intracellular antiviral
state. In many but not all cases, cells undergoing this response
also synthesize and secrete alpha/beta interferon (IFN-a/b)
(49), which renders neighboring uninfected cells resistant to
virus infection. IFNs are pleiotropic cytokines that mediate
antiviral and antiproliferative responses and modulate the im-
mune system (42). IFN-a and -b and IFN-g signal through
distinct, yet related, pathways in a rapid and direct manner.
Binding of IFN-a/b to its cell surface receptor induces the
tyrosine kinases Tyk2 and JAK1 to phosphorylate STAT-1 and
STAT-2, enabling these proteins to bind p48 and form the
IFN-stimulated gene factor 3 (ISGF3) complex. This complex
translocates to the nucleus, where it binds to the IFN-stimu-
lated response element (ISRE) and activates transcription.
Many IFN-stimulated genes (ISGs) encode proteins that con-
tribute to the antiviral state. For example, the double-stranded
RNA (dsRNA)-dependent protein kinase R (PKR) phosphor-
ylates eIF-2a, resulting in inhibition of protein synthesis, and
activated 29359 oligoadenylate synthetase (OAS) produces
2-5A, which in turn activates RNase L, resulting in mRNA
degradation (42).
ISGs can also be directly activated by dsRNA or virus infec-
tion in the absence of IFN (2, 44). These responses presumably
act to limit virus replication in the first cells that are infected in
a tissue or organism. IFN, dsRNA, and virus infection each
utilize a different signaling pathway for induction of mRNA
from an ISG coding for a protein with a molecular weight of
56,000 (ISG 56K) in human fibrosarcoma cells (11, 16, 50). The
degree of overlap between these signaling pathways has yet to
be precisely defined; however, they all appear to converge on
the ISRE. Several viruses stimulate the formation of alterna-
tive ISRE-binding transcription complexes that are distinct
from the ISGF3 induced by IFN. For example, Sendai virus
induces a novel transcriptional activator complex composed of
the IFN regulatory factor proteins IRF-3 and IRF-7, along
with several transcriptional coactivator proteins, that binds the
ISRE of the ISG 15K gene (50). Similarly, measles virus in-
duces the C-X-C chemokine IFN-inducible protein 10 (IP-10)
through the same ISRE as IFN-a, but with a different tran-
scription factor (29). Human cytomegalovirus (HCMV) in-
duces IFN-responsive RNAs in the absence of viral and cellu-
lar protein synthesis following binding of viral glycoprotein B
(gB) to an unknown cell surface receptor (4, 53, 54). HCMV-
induced activation of the ISG 54K gene is STAT independent
and is mediated by a novel transcriptional activator complex
that contains IRF3 (28).
Here, we studied the transcriptional response of human cells
to infection with herpes simplex virus type 1 (HSV-1). HSV-1
is a large enveloped DNA virus composed of an icosahedral
capsid surrounded by an amorphous tegument that contains
proteins that become available to the virus immediately fol-
lowing penetration of the host cell (37). During the lytic cycle,
HSV genes are expressed in a tightly regulated temporal cas-
cade beginning with transcription of the immediate-early (IE)
genes. The IE genes are activated by the virion-associated
transactivator, VP16, through a specific sequence motif within
their promoters (33). HSV-1 encodes five IE proteins: ICP-0,
-4, -22, -27, and -47. The first four are nuclear regulators that
activate expression of the viral early and late genes (37), while
ICP47 blocks a host antigen presentation pathway (52).
We have previously reported the construction and charac-
terization of KM110, an HSV-1 mutant bearing lesions that
eliminate the transactivation functions of VP16 and ICP0 (26).
KM110 is incapable of launching the lytic program of viral
gene expression in most cell types, and human embryonic lung
(HEL) fibroblasts survive infection with KM110, with no evi-
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dence of viral gene expression. Here we use the KM110 isolate
to show that the HSV particle induces an IFN-independent
antiviral state that protects cells from infection by several RNA
and DNA viruses. The antiviral state is induced in the absence
of viral gene expression. Microarray analysis of 19,000 human
expressed sequence tags (ESTs) revealed induction of a limited
set of host genes, many of which are also induced by IFN.
Wild-type HSV-1 also induced the same set of cellular genes,
but only when viral gene expression was inhibited. Thus, the
HSV particle induces an IFN-independent cellular antiviral
response that is subsequently disarmed following the onset of
viral gene expression.
MATERIALS AND METHODS
Viruses and cells. HEL, U2OS, and Vero cells, obtained from the American
Type Culture Collection, were maintained in Dulbecco’s minimal essential me-
dium (DMEM) supplemented with 10% (HEL and U2OS) or 5% (Vero) fetal
bovine serum (FBS). Vesicular stomatitis virus (VSV) and the HSV-1 strains
KOS, d22lacZ (ICP222) (23), N38 (ICP472) (46), and DICP6 (ICP62) (15) were
propagated on Vero cells. HSV-1 strains n212 (ICP02) (7), dlX3.1 (ICP02) (39),
V422 (VP162) (21), and KM110 (VP162 ICP02) (26) were propagated on
U2OS cells in the presence of 3 mM hexamethylene bisacetamide (Sigma, St.
Louis, Mo.). HSV-1 mutants bearing lesions in essential genes were grown on
their respective complementing cell lines as follows: 5dl1.2 (ICP272) was grown
on V27 cells (35), d120 (ICP42) was grown on E5 cells (10), K082 (gB2) (6) was
grown on VB38 cells (Vero cells containing the HSV-1 gB gene under the control
of its own promoter using histidinol as a selection marker; kindly provided by D.
Johnson, Oregon Health Sciences University, Portland), and F-gDb (gD2 gI2)
and F-US6kan (gD2) were grown on VD60 cells (18, 22). UV inactivation of
HSV-1 was performed with a UV Stratalinker 2400 (Stratagene) for a period of
1 min. The treatment reduced viral titers by a factor of ;104 (data not shown).
KOS virions were purified by banding on a dextran gradient as previously de-
scribed (26).
Plaque reduction assay. HEL cells were seeded in 12-well dishes such that
monolayers were completely confluent the next day. Monolayers were then mock
infected or infected with the indicated virus at a multiplicity of infection (MOI)
of 5 in serum-free DMEM for 1 h followed by replacement with DMEM con-
taining 5% FBS. Universal IFN-a (Research Diagnostics, Inc.) was added to
mock-infected samples at 1,000 U/ml. Twenty-four hours later, monolayers were
inoculated with approximately 100 PFU of VSV, followed by replacement with
DMEM containing 0.5% methylcellulose. Monolayers were fixed and stained
24 h later.
RNA extraction and Northern blot analysis. Total cellular RNA was extracted
from 100-mm-diameter dishes of infected cells by using Trizol (Gibco BRL)
according to the manufacturer’s instructions. Where indicated, cycloheximide
(100 mg/ml) was added 1 h prior to infection and maintained continuously.
Aliquots (5 mg) were subjected to electrophoresis as previously described (26).
Membranes were hybridized to a 32P-labeled probe generated by random prim-
ing in ExpressHyb buffer (Clonetech) as specified by the manufacturer. The ISG
56K and stress 70 chaperone probes were derived from IMAGE Consortium
clones 325364 and 27801, respectively.
DNA microarrays. DNA microarrays comprising about 19,000 human EST
clones were printed at the Microarray Centre (Ontario Cancer Institute, To-
ronto, Ontario, Canada) on CMT-GAPS aminosaline-coated glass slides (Corn-
ing, N.Y.) with a 32-pin contact arrayer (SDDC II; Engineering Services, Inc.).
The genes were arrayed in duplicate on two slides, each bearing 9,500 clones
spotted in duplicate. Detailed information on the layout of the microarrays can
be found on the website of the Microarray Centre (http://www.oci.utoronto.ca/
services/microarray).
Microarray analysis. Total cellular RNA was harvested from 107 cells with 7.5
ml of Trizol. For each microarray, 10 mg of total RNA was reverse transcribed
with 400 U of SuperScript II (Gibco, Life Technologies) in a total reaction
volume of 40 ml. The reverse transcription was primed with an AncT primer
(T20VN; Sigma Genosys) and performed in the presence of dATP, dGTP, and
dTTP (Pharmacia; final concentration of 168 mM each); dCTP (Pharmacia; final
concentration of 50 mM); and Cy3-dCTP or Cy5-dCTP (NEN; final concentra-
tion of 50 mM). Twenty units of RNasin (Promega) was added to each reaction
mixture. The mixture (minus the enzyme) was heated at 65°C for 5 min and then
at 42°C for 5 min. The reverse transcriptase was added, and the reaction mixture
was incubated at 42°C for 2 h. The reverse transcription was stopped with 6.25
mM EDTA, and the RNA template was degraded by the addition of 0.5 N
NaOH, followed by incubation at 65°C for 20 min. The mixture was neutralized
by the addition of 0.5 M acetic acid, and the labeled cDNA was precipitated by
adding 1 volume of isopropanol and incubating on ice for 30 min. After rinsing
with 70% ethanol, the labeled cDNA was resuspended in 3 ml of DNase-free,
RNase-free water (Sigma). In order to eliminate labeling biases, two pairs of
slides were hybridized for each pair of samples: one pair in which the control
RNA was labeled with Cy3 and the experiment RNA was labeled with Cy5 and
one pair in which the control RNA was labeled with Cy5 and the experiment
RNA was labeled with Cy3.
For hybridization, 3 ml of purified Cy3-labeled cDNA and 3 ml of purified
Cy5-labeled cDNA were added to 75 ml of DIG Easy hybridization buffer
(Boehringer Mannheim). Two microliters of yeast tRNA (Sigma; 10 mg/ml) and
2 ml of single-stranded salmon sperm DNA (Sigma; 10 mg/ml) were added to the
hybridization mixture, and the solution was heated at 65°C for 2 min. This
solution was then carefully pipetted between two microarrays (parts 1 and 2)
placed face to face. The slides were incubated at 37°C in a humid hybridization
chamber for 8 to 12 h. Before scanning, the slides were washed in 0.13 SSC (13
SSC is 0.15 M NaCl plus 0.015 M sodium citrate)–0.1% sodium dodecyl sulfate
(three times for 15 min at 50°C), rinsed in 0.13 SSC (three times for 5 min each
at room temperature), and dried by centrifugation. The arrays were read on a
laser confocal scanner (ScanArray 4000; GSI Lumonics), and the images ob-
tained were quantified by using the QuantArray 2.0 software (GSI Lumonics).
Normalization of the raw data and analysis of the data sets were performed with
an algorithm developed in house (A. B. Goryachev et al., unpublished data).
Production and quantitation of glycoprotein-deficient viruses. Vero cells (2 3
107) were inoculated with KOS, F-gDb, F-US6kan, or K082 at an MOI of 5. Two
days later, cells were harvested and then spun at 1,400 3 g for 7 min, and the
pellets were resuspended in 1 ml of serum-free DMEM. Following three freeze-
thaw cycles and sonication, samples were respun to pellet cellular debris, and the
supernatant was harvested. The titers of the resulting virus stocks were deter-
mined on Vero cell monolayers. Titers of F-gDb, F-US6kan, and K082 were
reduced by a factor of ;104 compared to KOS (data not shown). In order to
standardize the number of viral particles used in subsequent experiments, par-
ticles were counted in the presence of a fixed amount of 90-nm-diameter poly-
styrene latex particles (Dow Diagnostics) by using a Philips model 410 transmis-
sion electron microscope. The volume of F-gDb, F-US6kan, or K082 virus stock
used was adjusted accordingly in order to inoculate cells with the same number
of viral particles calculated for a specific MOI for KOS.
RESULTS
HSV-1 virions induce an antiviral state in the absence of de
novo viral gene expression. The HSV-1 mutant KM110 bears
mutations that inactivate the transactivation functions of VP16
and ICP0 and therefore cannot launch the lytic program of
viral gene expression (26). HEL fibroblasts infected with
KM110 display no evidence of viral gene expression and sur-
vive for at least 10 days in culture after virus inoculation. We
asked if cells infected previously with KM110 displayed altered
susceptibility to subsequent virus infection. HEL monolayers
were either mock infected or infected with 5 PFU of KM110
per cell and then superinfected 24 h later with ca. 100 PFU of
wild-type HSV-1 KOS, VSV, or vaccinia virus per monolayer.
All three superinfecting viruses produced the expected number
of plaques on mock-infected monolayers, but no plaques were
observed on HEL monolayers that had been previously in-
fected with KM110 (Fig. 1 [only the data obtained with VSV
are shown]). KM110 retained the ability to block VSV plaque
formation even when its genome was inactivated by irradiation
with UV light, confirming that development of resistance does
not require expression of the KM110 genome. UV-inactivated
wild-type HSV-1 strain KOS also blocked plaque formation by
all three viruses, showing that the antiviral effect is not specific
to the KM110 mutant (Fig. 1). KOS virions retained UV-
resistant antiviral activity following purification by banding on
a dextran gradient, indicating that the effect is induced by
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virions rather than a soluble factor present in the virus inocu-
lum (Fig. 1). HEL cells did not develop resistance to VSV
following exposure to medium harvested from KM110-infected
cells (data not shown), arguing that HSV-1 virions do not
induce the production of functional levels of IFN or other
factors capable of inducing an antiviral state. Taken in combi-
nation, these data suggest that HSV-1 virions are capable of
inducing a nonspecific, IFN-independent antiviral state in the
absence of de novo viral gene expression.
HSV-1 virions induce expression of host genes involved in
antiviral defense. The foregoing data suggested that HSV-1
virions induce a host antiviral defense mechanism in the ab-
sence of viral gene expression. We therefore asked if HSV-1
virions induce expression of specific cellular genes, using DNA
microarrays that comprise over 19,000 unique human genes or
ESTs. Duplicate cultures of HEL cells were mock infected,
infected with virus (KM110, KOS, or UV-inactivated KOS), or
treated with IFN-a. Total cellular RNA isolated 24 h later was
used to generate cDNA for DNA microarray analysis. Approx-
imately 10,000 of the 19,000 genes represented on the microar-
rays were expressed at levels enabling detection and quantifi-
cation with statistical confidence (A. B. Goryachev et al.,
unpublished data). Genes whose expression levels changed
more than a factor of 2 (up or down) in at least one of two
experiments between the infected or IFN-treated and mock-
infected cells were identified (Table 1). Both KM110 and UV-
inactivated KOS increased the levels of expression of a small
set of cellular genes (33 and 32, respectively). The two sets
were highly related, with 27 genes common to both. Strikingly,
20 of these 27 shared genes were also induced by IFN-a. Most
of the genes thus identified that were not common to all of the
IFN, KM110, and UV-inactivated KOS data sets had induction
ratios close to the cutoff for inclusion (and/or scored as positive
in only one of the duplicates).
Infection with the wild-type KOS virus had a more dramatic
effect on cellular mRNA levels. However, only two of the genes
whose expression was changed by infection with KM110 or
UV-inactivated KOS or after treatment with IFN-a were also
altered after KOS infection. In both cases, the level of expres-
sion was decreased by KOS, but increased by the other treat-
ments (Table 1). A comprehensive analysis of the effects of
wild-type HSV-1 on cellular gene expression will be presented
elsewhere.
We drew two broad conclusions from the microarray data.
First, KM110 and UV-inactivated KOS increase the expression
of remarkably similar sets of cellular genes, which overlap
extensively with those induced by IFN-a. Some of the proteins
encoded by the genes that are common to all three sets act to
limit intracellular virus replication (e.g., MX1, OAS, and
PML) (42), and others serve as secreted proinflammatory che-
mokines (e.g., SCYB10 [also known as IP-10] and ISG15) (1).
Second, wild-type HSV-1 does not induce the expression of
any of these genes, implying that induction of IFN-responsive
genes occurs only when viral gene expression is inhibited.
The transcriptional activation function of VP16 prevents
induction. Transcriptionally inactive HSV-1 (KM110 and UV-
inactivated KOS) induced IFN-responsive genes, but transcrip-
tionally competent virus did not. One possibility is that HSV-1
produces one or more gene products shortly after infection
that block the cellular response to the infecting virion. To
further investigate this possibility and to validate the results of
the microarray analysis, we monitored the accumulation of
ISG 56K RNA as an indicator of viral gene induction by using
Northern blot analysis (Fig. 2). ISG 56K, which encodes a
56-kDa IFN-inducible protein, is one of the transcripts most
strongly induced by KM110 (Table 1). Northern blot analysis
confirmed that ISG 56K message is strongly induced by KM110
and UV-inactivated KOS, but does not accumulate following
infection with wild-type KOS. However, KOS strongly induced
ISG 56K mRNA when the infection was carried out in the
presence of cycloheximide, confirming that wild-type virus is
competent for induction when viral protein synthesis is blocked
and demonstrating that the response does not require cellular
protein synthesis.
The genetic basis for the ability of untreated KM110 to
induce the transcriptional response was determined. KM110
bears two separate mutations: the V422 lesion truncates the
C-terminal acidic transcriptional activation domain of VP16
after residue 422 (21), and the n212 mutation truncates the IE
protein ICP0 after residue 212 (7). As shown in Fig. 2, a virus
bearing only the V422 mutation triggered induction of ISG
56K RNA as efficiently as did KM110. In contrast, the n212
mutant failed to induce this transcript. Therefore, truncation
of the transcriptional activation domain of VP16 is associated
with the induction of the ISGs.
VP16 is a component of the infecting virion that acts during
the very earliest stages of infection to stimulate transcription of
the five viral IE genes (33). It also serves an essential structural
role in virion assembly and egress (25, 51). The V422 mutation
FIG. 1. Induction of an antiviral state by HSV-1 KM110 and UV-
inactivated wild-type KOS. HEL monolayers were mock infected
(mock, IFN) or infected with KM110 (with [1] or without [2] UV
inactivation) or UV-inactivated KOS at an MOI of 5. IFN-a was added
at 1,000 U/ml following the infection. The next day, ;100 PFU of VSV
was added to each well, and monolayers were stained 24 h later. A
similar inhibition of plaquing was observed for HSV-1 KOS and vac-
cinia virus (data not shown).
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abolishes the transcriptional activity of VP16, but leaves its
structural functions intact (21). The V422 mutation might
therefore unmask inducing activity, because V422 virions,
which are devoid of transcriptionally competent VP16, are less
able to synthesize a possible inhibitor of induction. If so, then
one would predict that V422 virions would be unable to induce
ISG gene expression when loaded with wild-type VP16. We
generated a V422 virus stock harboring wild-type VP16 by
passaging the virus on 16-8 cells that provide wild-type VP16 in
trans. The resulting complemented virions were then used to
infect HEL cells. Unlike noncomplemented virions, the com-
plemented virions failed to induce the ISG 56K RNA (Fig. 3).
However, inducing activity was restored when the genome of
the complemented virus was inactivated with UV irradiation.
The differences in intensity between V422 and UV-inactivated
V422 seen in Fig. 2 and 3 are not consistent between individual
TABLE 1. Microarray analysis of IFN-treated and HSV-1-infected HEL cells
Accession
no. Gene or gene product and description
Relative change in level of expression
KOS UV-treatedKOS KM110 IFN-a
Set A Set B Set A Set B Set A Set B Set A Set B
AA193601 MX1, myxovirus (influenza virus) resistance 1, homolog of murine
(IFN-inducible protein p78)
20.06 7.68 10.08 7.40 16.55 7.44
R82716 ISG15, IFN-stimulated protein, 15 kDa 18.33 16.53 20.46 11.83 16.55 13.88
N63988 EST 13.69 9.1 6.25 6.21
W52254 IFIT1, IFN-induced protein 56 9.83 12.05 4.93 7.72 6.16 4.57
AA152305 SCYB10, small inducible cytokine subfamily B (Cys-X-Cys),
member 10
7.63 2.81 2.42 2.58
W49782 MX1, myxovirus (influenza virus) resistance 1, homolog of murine
(IFN-inducible protein p78)
6.45 4.59 3.78 3.55 —a 5.17
AA035361 STAT1, signal transducer and activator of transcription 1, 91 kDa 6.33 4.13 3.94 3.48 4.37 3.08
T95113 Homo sapiens cig5 mRNA, partial sequence 5.57 2.18 4 1.61 2.01 1.4
R76719 EST, weakly similar to GEF-2 protein (H. sapiens) 5.38 4.76 6.53 4.27 8.2 6.78
R09187 EST 5.18 2.63 4.87 1.82 2.6 2.29
AA035024 MX2, myxovirus (influenza virus) resistance 2, homolog of murine 4.68 2.03 2.9 1.92
T92814 EST, homolog to H. sapiens cig41 4.5 2.91 3.41 3.07 2.54 2.28
H49854 IFITM1, IFN-induced transmembrane protein 1 (9–27) 4.43 4.49 5.69 4.41 6.69 5.38
AA046075 EST 3.9 2.91 2.38 1.92 2.33 2.15
R59506 EST, homologue to H. sapiens cyclin-E binding protein 3.85 2.13 2.92 1.64
AA043535 IMAGE-487558 3.31 1.98 2.34 2.14 2.46 2.15
W47619 OAS3, 29359 oligoadenylate synthetase 3 2.99 2.13 2.73 2.26 2.13 2.46
N63887 EST, weakly similar to TYKi protein (Mus musculus) 2.81 1.75 2.21 1.67
N43008 SP100, nuclear antigen Sp100 2.81 1.91 2.23 1.77 2.38 2.38
T74462 ABCB2, ATP-binding cassette, subfamily B (MDR/TAP), member
2
2.77 2.03 2.44 1.4 2.21 1.67
R34567 OAS2, 29359 oligoadenylate synthetase 2 2.59 1.93 2.3 1.71 2.21 2.45
H70440 GS3686, hypothetical protein, expressed in osteoblast 2.48 2.06 3.29 1.41 2.28 1.95
T86070 EST 2.42 1.88 2.08 1.66
R23341 B2M, b-2-microglobulin 2.3 1.91 3.09 1.94 2.83 2.29
W94862 ADAR, adenosine deaminase, RNA specific 2.29 1.94 2 1.95
AA028065 BRF2, butyrate response factor 2 (EGF-response factor 2) 2.25 1.93
W47350 RARRES3, retinoic acid receptor responder (tazarotene induced)
3
2.13 1.97 2.03 1.95
T80567 KIAA072, KIAA0725 protein 2.02 1.74 2.31 1.5
AA001748 EST, weakly similar to angiopoietin Y1 (H. sapiens) 2.01 2.35
AA040506 IMAGE-485950 2 1.75
AA040032 KIAA0015, KIAA0015 gene product 0.55 0.36 1.99 2.37 2.04 2.18 3.37 3.59
W63787 PHGDH, b-phosphoglycerate dehydrogenase 0.42 0.5
R13977 EST 0.37 0.43 0.52 0.47
R80595 SOD2, superoxide dismutase 2, mitochondrial 3.7 1.81
H60340 IMAGE-207631 1.78 2.08
H17813 TOP2A, topoisomerase II alpha 0.48 0.48
R40483 Homo sapiens clone 24877 mRNA sequence 3.31 1.85
N34456 NT5, 59 nucleotidase (CD73) 2.19 1.83
AA040062 EST, weakly similar to yeast antiviral protein SK12 and ATP-
dependent DNA helicase
3.65 1.48 2.84 2.14 2 1.59
N58703 IMAGE-247579 2.1 1.51 2.15 1.89
W88741 EST 5.41 44.08
N30287 EST, weakly similar to Wiscott-Aldrich syndrome protein
homolog
2.32 2.58
W67568 HLA-A, MHC class I, A 0.43 0.18 2.64 3.21
AA053162 HLA-B, MHC class I, B 2.42 2.32
W00378 HLA-C, MHC class I, C 2.22 2.43
a —, Intensity of the spot on the array was below local background.
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experiments and thus are not significant. These data demon-
strate that the V422 mutant induces ISG 56K RNA, because
V422 virions lack wild-type VP16.
Induction requires viral entry. HCMV virions trigger ex-
pression of host IFN-inducible genes, and soluble HCMV gly-
coprotein B (gB) is apparently sufficient to induce this effect (4,
54). Presumably, gB located in the envelope of the infecting
HCMV virion binds to a cell surface receptor and activates
intracellular signaling events. These data imply that HCMV
need not enter the host cell in order to induce cellular gene
expression. We asked if entry is required for HSV-1 to induce
the expression of ISG 56K mRNA. To accomplish this, we
examined the phenotypes of several HSV-1 mutants that are
competent to bind to the cell surface, but are unable to pen-
etrate the plasma membrane.
HSV entry is a multistep process that requires many viral
envelope glycoproteins (34). gC (and to a lesser extent, gB)
binds to heparin sulfate proteoglycans, providing the initial
attachment to the cell surface. gD then interacts with several
cell surface receptors, and the virion envelope fuses with the
host plasma membrane by using gB, gD, gH, and gL. Viral
isolates bearing null mutations in the genes encoding the gly-
coproteins required for membrane fusion must be propagated
on complementing cells that provide the missing glycoprotein
in trans. The complemented virions that result are capable of
one round of productive infection on noncomplementing cells,
producing noninfectious (noncomplemented) virions that are
competent to bind to the cell surface, but are unable to pen-
etrate (6, 14, 18, 38). Noncomplemented virions lacking gD
and gI (F-gDb), gD (F-US6kan), or gB (KO82), which are
unable to enter cells, did not induce ISG 56K RNA, even after
UV inactivation; in contrast, the corresponding complemented
virions, which are able to enter cells, showed efficient induction
when they were UV inactivated (Fig. 4). The simplest inter-
pretation of this result is that induction requires viral entry into
host cells.
Evidence for a potential virus-encoded inhibitor of the an-
tiviral response. We attempted to determine if a viral gene
product(s) is responsible for blocking the antiviral response
during HSV infection by surveying the phenotypes of selected
mutant viruses. The IE protein ICP4 is the major HSV tran-
scriptional regulator and is stringently required for expression
of the viral early and late genes (37). Previous work showed
that the ICP4 null mutant, d120, synthesizes only ICP0, ICP22,
ICP27, ICP47, and ICP6, albeit at exaggerated levels (10). The
d120 mutant failed to efficiently induce ISG 56K RNA (unless
the virus was first UV inactivated) suggesting that ICP4 is not
required to block the response (Fig. 5). The simplest interpre-
tation of this finding is that one or more of the other IE
proteins and/or ICP6 normally acts to block induction (al-
though it remains possible that overproduction of these pro-
teins contributes to the d120 phenotype). Noteably, ISG 56K
RNA was not induced in cells infected with any of a panel of
viral mutants bearing lesions that individually inactivate each
of these proteins (Fig. 5). The difference in intensity of signal
between UV-inactivated viruses is not reproducible and thus is
not significant. One interpretation of these results is that
HSV-1 encodes two or more proteins that are each sufficient to
block the response. Another is that induction is not detected
when viral gene expression is allowed to proceed, because
HSV-induced delayed shutoff of the cellular gene precludes or
masks the response. Consistent with this interpretation, both
KOS and complemented V422 caused a large decline in the
levels of mRNA derived from the cellular gene encoding the
60-kDa stress 70 protein chaperone by 24 h postinfection (Fig.
6). However, stress 70 mRNA levels did not decline following
infection with d120 or 5dl1.2 (Fig. 6), indicating that these
isolates do not globally shut off cellular gene expression. Taken
together, these data suggest that wild-type infection may in-
deed preclude induction of an antiviral response through a
general host shutdown mechanism. This explanation, however,
seems insufficient to explain the lack of a response during
infection with a number of IE mutant viruses, lending support
to the idea that the virus may in fact produce one or more
specific inhibitors.
FIG. 2. Northern blot analysis of ISG 56K RNA. HEL cells were mock infected (M, IFN) or infected with the indicated virus (with [1] or
without [2] UV inactivation) at an MOI of 5. Where indicated, cycloheximide (CHX) was added at 100 mg/ml 1 h prior to infection and maintained
throughout. At 24 h postinfection, RNA was extracted and analyzed for ISG 56K RNA levels by Northern blot hybridization.
FIG. 3. Induction of ISG 56K RNA by V422 is suppressed by load-
ing wild-type VP16 into mutant virions. HEL cells were infected with
V422 grown on either U2OS cells (noncomplemented virions) or 16-8
cells (Vero cells that provide VP16 in trans [complemented virions]) at
an MOI of 5 (with [1] or without [2] UV inactivation). At 24 h
postinfection, RNA was extracted and analyzed for ISG 56K RNA
levels by Northern blot hybridization.
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Induction by HSV-1 virions can be uncoupled from IFN
signaling. We have shown previously that although HEL cells
fail to support growth of KM110, this virus replicates efficiently
on the human osteosarcoma cell line U2OS (26). In order to
determine if HSV virions induce a response in U2OS cells
similar to that seen in HEL cells, we monitored ISG 56K RNA
induction in U2OS cells treated with IFN-a or infected with
KOS, UV-inactivated KOS, or KM110. ISG 56K RNA was not
induced by any of the viruses in U2OS cells. However, ISG 56K
RNA was induced in U2OS cells after treatment with IFN,
demonstrating that these cells have a functional IFN signaling
cascade (Fig. 7). Entirely analogous results were obtained for
the mRNA encoding the C-X-C chemokine IP-10, which was
induced by IFN and HSV-1 virions in HEL cells, but only by
IFN in U2OS cells (data not shown). These data argue that
HSV-1 virions do not trigger expression of IFN response genes
by engaging the IFN receptor and demonstrate that our virion
preparations lack detectable IFN activity. They also suggest a
possible correlation between the permissiveness of a given cell
line for KM110 and the appearance of an IE cellular transcrip-
tion response.
DISCUSSION
Treatment of cells with IFN rapidly induces an antiviral state
(42). Here, we show that HSV-1 virus particles that are inca-
pable of gene expression produce a similar effect. Induction of
the antiviral state by HSV-1 is inhibited by viral gene expres-
sion and occurs in an IFN-independent fashion. The HSV-
induced antiviral state is linked to enhanced expression of a
specific set of cellular genes, many of which are also induced by
IFN. Some of these genes, such as those coding for MX1/2,
OAS2/3, and b-2-microglobulin, are known to limit intracellu-
lar virus replication (42). MX proteins are dynamin superfam-
ily GTPases that interfere with viral replication at many levels.
The OAS pathway activates RNase L and leads to degradation
of viral mRNAs. b-2-Microglobulin is required for expression
of major histocompatibility complex (MHC) class I molecules,
which are critical for recognition and lysis of virally infected
cells by T cells. Other induced cellular genes, such as ISG15
and IP-10, serve as proinflammatory cytokines (1); IP-10 has
been implicated as an important mediator of Th1 dominant
immune responses (48). Induction appears to require viral
penetration, but does not occur when viral gene expression is
FIG. 4. Viral penetration is required for induction of ISG 56K RNA. HEL cells were infected with HSV-1 KOS (MOI 5) or the indicated
glycoprotein mutants (with [1] or without [2] UV inactivation). Mutants grown on their respective complementing cell line were used to infect
monolayers at an MOI of 5 PFU/cell. Mutants grown for one round on noncomplementing Vero cells produce viral particles, the titers of which
cannot be determined due to their inability to penetrate. Thus, viral particles were counted with a transmission electron microscope (see Materials
and Methods), and the inoculum was adjusted so that a dose of viral particles equivalent to an MOI of 5 PFU of KOS per cell was used. At 24 h
postinfection, RNA was extracted and analyzed for ISG 56K RNA levels by Northern blot hybridization.
FIG. 5. HSV-1 may disarm the antiviral response by synthesizing an inhibitor. Viral mutants bearing mutations that inactivate individual IE
genes were used to infect HEL cells (with [1] or without [2] UV inactivation) at an MOI of 5. At 24 h postinfection, RNA was extracted and
analyzed for ISG 56K RNA levels by Northern blot hybridization.
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permitted, implying that HSV encodes one or more gene prod-
ucts that normally act to disarm the response. A recent report
by Preston and colleagues found that HSV-1 induces expres-
sion of four IFN-inducible genes if viral gene expression is
blocked, in a process that does not require cellular protein
synthesis (31).
Differential display and microarray analysis showed previ-
ously that the related herpesvirus HCMV induces IFN-respon-
sive RNAs in primary human fibroblasts (53, 54). The HSV-
induced response described in this report is similar to that
induced by HCMV in that induction does not require viral
gene expression or cellular protein synthesis. However, the
response to HSV is evident only when viral gene expression is
blocked, while HCMV induces IFN response genes even when
viral gene expression is allowed to proceed. In addition, puri-
fied HCMV gB suffices to induce the response (4), implying
that binding of HCMV virions to the cell surface is sufficient,
while our data strongly argue that HSV-1 must penetrate the
plasma membrane in order to induce. Several aspects of the
HSV-induced cellular response are common to other viral sys-
tems. Adenovirus capsids induce the expression of multiple
chemokines, including IP-10 (3, 19, 27), in the absence of viral
gene expression, while the human immunodeficiency and Ep-
stein-Barr viruses induce a cellular response following virus
attachment (5, 36, 43). Attachment, penetration, and limited
viral transcription suffice for induction of the chemokine
RANTES during infection with measles virus (32).
While the signaling pathway used in the HSV-induced re-
sponse remains to be identified, it apparently does not involve
signaling through the IFN receptors: U2OS cells respond to
IFN, yet fail to show expression of ISG 56K mRNA upon
infection with either KM110 or UV-inactivated KOS. A similar
conclusion using cell lines mutated for Tyk2, JAK1, or STAT1
was recently reported (31). Our data indicate that induction
requires viral penetration of the host plasma membrane, but
occurs in the absence of viral transcription. A number of IFN-
responsive genes, including ISG 56K, can be induced directly
by dsRNA in the absence of IFN (2, 44). However, dsRNA is
unlikely to be involved in the response to HSV, because viral
transcription is not required. Our data therefore suggest that
HSV activates a novel intracellular sensor that detects a very
early step during virus infection. Possible inducing events in-
clude fusion of the viral envelope with the host plasma mem-
brane, introduction of viral tegument proteins into the cyto-
plasm, or changes in the cytoskeleton, because HSV capsids
are transported to the nucleus via microtubules (41) and the
HSV-1 tegument protein VP22 exhibits the properties of a
microtubule-associated protein (12). Alternatively, it is possi-
ble that delivery of viral DNA into the nucleus triggers the host
response. Further studies are required to distinguish between
these possibilities. The availability of cell lines such as U2OS
that are defective in this signaling pathway should facilitate
these studies.
Induction of the antiviral response occurs only when viral
gene expression is blocked, suggesting that a newly made gene
product may function as an inhibitor. The IE protein ICP4 is a
prominent HSV transcriptional regulator that is essential for
expression of viral early and late genes. Inasmuch as an ICP4
null mutant failed to efficiently induce ISG 56K in the absence
of UV inactivation, we concluded that any viral inhibitor must
be an IE gene product. However, mutants bearing lesions that
individually inactivate each IE protein failed to induce ISG
56K. Therefore, if a viral inhibitor does exist, then HSV-1
likely encodes two or more proteins that are each sufficient to
block the response. This apparent redundancy of inhibitors
may indicate that disarming the cellular antiviral response is of
great importance to the virus. We have recently shown that the
IE protein ICP0 contributes to the relative resistance of HSV-1
to IFN (24), indicating that ICP0 is capable of overcoming an
already established antiviral state. Thus, ICP0 is a likely can-
didate for one of the putative inhibitors.
The potential biological significance of the cellular response
to HSV particles is many fold. The efficiency of the cellular
response in a given cell type may influence the decision of
whether incoming viral genomes enter the lytic cycle or remain
quiescent. It will be interesting to learn if a similar virion-
induced response occurs during infection of neurons and in-
FIG. 6. Northern blot of cellular stress 70 protein chaperone
mRNA following infection with various HSV-1 recombinants. Wild-
type and mutant HSV-1 viruses were used to infect HEL cells (with or
without UV inactivation) at an MOI of 5. At 24 h postinfection, RNA
was extracted and analyzed for the cellular stress 70 protein chaperone
mRNA by Northern blot hybridization.
FIG. 7. HSV-1 does not induce ISG 56K RNA in the U2OS cell
line. HEL and U2OS monolayers were mock infected (mock, IFN) or
infected with KOS (with or without UV inactivation) or KM110 at an
MOI of 5. IFN-a was added at 1,000 U/ml following infection. At 24 h
postinfection, RNA was extracted and analyzed for ISG 56K RNA
levels by Northern blot hybridization.
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fluences the entry into latency. The response likely enhances
the ability of HSV to induce antiviral immunity in vivo and may
partly explain the self-limiting nature of HSV infections in the
intact human host. The response has potentially broad impli-
cations for gene therapy, which requires efficient transfer of the
therapeutic gene to the desired location and the sustained expres-
sion of that gene (47). HSV has been identified as a potentially
ideal vector for gene delivery, because the viral genome can ac-
cept insertions of multiple therapeutic genes and HSV can be
targeted to the nervous system (9, 13). However, current HSV
vectors have been designed to preclude expression of the viral IE
proteins in order to eliminate cytotoxicity (17, 40). Our results
predict that such vectors will trigger the host antiviral response in
the same fashion as KM110. Such a response would likely severely
limit the duration of transgene expression in vivo, through im-
mune-mediated clearance of the infected cells. In support of this
hypothesis, replication-defective recombinant adenoviral vectors
induce cytotoxic T lymphocytes capable of lysing infected cells
(19). In addition, the IFN-induced antiviral state blocks transcrip-
tion of both viral and heterologous promoters located in the HSV
genome (30), suggesting that the virion-induced antiviral state
would contribute to extinction of transgene expression. Consis-
tent with this possibility, HSV vectors that establish genome qui-
escence in the same fashion as KM110 support only very low
levels of expression of heterologous transgenes (17, 40).
Viruses both induce and evade host antiviral responses (8,
20, 45). Our data point to the existence of a novel IFN-inde-
pendent intracellular mechanism for detecting virus infection.
Deciphering the mechanisms by which HSV induces and dis-
arms this system will enhance our understanding of the basic
biology of virus-host interactions and aid in the rational design
of useful viral vectors for gene therapy.
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